New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
08:06 EDTSNY, ALNY, MRKGenzyme exercises right to purchase additional shares of Alnylam common stock
Alnylam (ALNY) announced that Genzyme, a Sanofi (SNY) company, has exercised its right to purchase 344,448 unregistered shares of Alnylamís common stock in accordance with the terms of an investor rights agreement between Alnylam and Genzyme, dated January 11. These shares became available for purchase by Genzyme as a result of Alnylamís issuance of shares of common stock to Merck (MRK) in connection with Alnylamís acquisition of Sirna Therapeutics. Under the investor rights agreement, Genzyme has the right to purchase additional shares to maintain its ownership percentage of the companyís common stock. On March 25, Genzyme purchased these additional shares at a purchase price of $66.88, the closing price of Alnylamís stock that day, and paid the company approximately $23M. The exercise of this right to purchase the maximum number of additional shares under the terms of the investor rights agreement allows Genzyme to maintain its current ownership level of Alnylam common stock of approximately 12%.
News For ALNY;SNY;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
11:56 EDTSNYSanofi initiated with a Buy at Societe Generale
Subscribe for More Information
08:33 EDTMRKFDA panel results positive for Merck, says SunTrust
Subscribe for More Information
07:41 EDTSNYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
13:32 EDTMRKMerck, NewLink Genetics confirm initiation of Phase 3 trial of Ebola vaccine
Subscribe for More Information
08:18 EDTALNYAlnylam data encouraging, says JMP Securities
Subscribe for More Information
April 13, 2015
11:02 EDTALNYAlnylam publishes pre-clinical results on ALN-AT3
Subscribe for More Information
10:15 EDTALNYHigh option volume stocks
Subscribe for More Information
08:58 EDTMRKMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
April 9, 2015
09:25 EDTMRKPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 8, 2015
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
06:57 EDTALNYAlnylam added to short-term buy list at Deutsche Bank
April 7, 2015
07:14 EDTMRK, SNYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use